All In Biotech

Drug Trial Radar · NCT07823348

JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer

A Phase III, Multicenter, Randomized, Controlled, Open-label Clinical Study to Evaluate the Efficacy and Safety of JS207 in Combination With JS007 Versus Toripalimab in Combination With Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 560 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

560

Planned (sponsor's estimate)

Start

Oct 8, 2026

Primary completion

Oct 30, 2029

Study completion Oct 30, 2031

Sponsor

Lead sponsor
Shanghai Junshi Bioscience Co., Ltd.Academic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, open-label, controlled Phase III clinical study designed to evaluate the efficacy and safety of JS207 in combination with JS007 versus toripalimab in combination with bevacizumab as first-line treatment in participants with advanced HCC. All study participants have unresectable locally advanced, recurrent, or metastatic HCC and have not previously received systemic anti-tumor therapy for advanced disease. Approximately 560 participants are planned to be enrolled in this study. The JS207 + JS007 group (experimental group) and the toripalimab + bevacizumab group (positive control group) are each planned to enroll 280 participants.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • JS207Drug

    PD-1/VEGF bispecific antibody supplied as a lyophilized powder for intravenous infusion.

  • JS007Drug

    CTLA-4 monoclonal antibody supplied as an injectable solution for intravenous infusion.

  • ToripalimabDrug

    PD-1 monoclonal antibody supplied as an injectable solution for intravenous infusion.

  • BevacizumabDrug

    VEGF monoclonal antibody supplied as an injectable solution for intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival Assessed by Blinded Independent Central Review (BICR-PFS)Time frame: From randomization to disease progression or death, whichever occurs first; assessed up to 24 months.
  2. Overall Survival (OS)Time frame: From randomization to death from any cause; assessed up to 66 months.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.